Opaleye Management as of June 30, 2016
Portfolio Holdings for Opaleye Management
Opaleye Management holds 49 positions in its portfolio as reported in the June 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Auris Med Hldg | 9.7 | $15M | 2.1M | 6.88 | |
| Nabriva Therapeutics | 7.2 | $11M | 2.0M | 5.55 | |
| Amarin Corporation | 6.2 | $9.2M | 1.3M | 7.39 | |
| Edge Therapeutics | 3.6 | $5.4M | 330k | 16.41 | |
| Ophthotech | 3.5 | $5.2M | 8.2M | 0.64 | |
| Biolinerx Ltd-spons | 3.4 | $5.1M | 250k | 20.25 | |
| Inotek Pharmaceuticals Corp conv | 3.2 | $4.8M | 645k | 7.44 | |
| Immunomedics | 3.2 | $4.8M | 1.3M | 3.76 | |
| Chimerix (CMRX) | 3.2 | $4.7M | 1.2M | 4.03 | |
| Achaogen | 3.0 | $4.5M | 300k | 15.14 | |
| Evoke Pharma | 3.0 | $4.4M | 695k | 6.35 | |
| Blueprint Medicines (BPMC) | 2.7 | $4.0M | 835k | 4.81 | |
| Agios Pharmaceuticals (AGIO) | 2.5 | $3.8M | 1.8M | 2.16 | |
| Adaptimmune Therapeutics (ADAP) | 2.4 | $3.6M | 85k | 41.89 | |
| Foamix Pharmaceuticals | 2.2 | $3.3M | 200k | 16.47 | |
| Ultragenyx Pharmaceutical (RARE) | 2.1 | $3.2M | 65k | 48.91 | |
| Medivation | 2.0 | $3.0M | 112k | 26.99 | |
| Geron Corporation (GERN) | 2.0 | $3.0M | 1.3M | 2.32 | |
| Intec Pharma | 2.0 | $3.0M | 650k | 4.60 | |
| Affimed Therapeutics B V | 1.9 | $2.9M | 120k | 23.92 | |
| Cara Therapeutics | 1.8 | $2.7M | 675k | 3.93 | |
| Sage Therapeutics (SAGE) | 1.7 | $2.5M | 125k | 20.37 | |
| Fibrogen | 1.7 | $2.5M | 152k | 16.59 | |
| Xenon Pharmaceuticals (XENE) | 1.6 | $2.4M | 410k | 5.90 | |
| DepoMed | 1.5 | $2.3M | 226k | 10.11 | |
| Medgenics | 1.4 | $2.1M | 260k | 8.10 | |
| Corium Intl | 1.4 | $2.1M | 125k | 16.75 | |
| Ohr Pharmaceutical | 1.4 | $2.0M | 147k | 13.91 | |
| Nektar Therapeutics | 1.4 | $2.0M | 270k | 7.50 | |
| AMAG Pharmaceuticals | 1.3 | $2.0M | 295k | 6.62 | |
| Cytrx | 1.3 | $1.9M | 50k | 38.80 | |
| XOMA CORP Common equity shares | 1.3 | $1.9M | 240k | 8.05 | |
| Trillium Therapeutics, Inc. Cmn | 1.2 | $1.8M | 195k | 8.98 | |
| Retrophin | 1.1 | $1.7M | 58k | 29.04 | |
| Cynapsus Therapeutics | 1.1 | $1.6M | 160k | 10.21 | |
| Tg Therapeutics (TGTX) | 1.1 | $1.6M | 800k | 1.99 | |
| Adamas Pharmaceuticals | 1.0 | $1.5M | 595k | 2.48 | |
| Imprimis Pharmaceuticals | 1.0 | $1.5M | 265k | 5.51 | |
| Ariad Pharmaceuticals | 0.9 | $1.4M | 340k | 4.19 | |
| Nivalis Therapeutics | 0.9 | $1.3M | 260k | 4.95 | |
| Protalix Biotherapeutics Inc note 4.500% 9/1 | 0.8 | $1.3M | 105k | 12.13 | |
| Codexis (CDXS) | 0.8 | $1.2M | 360k | 3.47 | |
| Supernus Pharmaceuticals (SUPN) | 0.8 | $1.2M | 465k | 2.56 | |
| Tenax Therapeutics | 0.7 | $1.1M | 175k | 6.06 | |
| Eagle Pharmaceuticals (EGRX) | 0.6 | $891k | 130k | 6.85 | |
| Neuroderm Ltd F | 0.6 | $853k | 53k | 16.25 | |
| Chiasma | 0.3 | $443k | 43k | 10.30 | |
| Aclaris Therapeutics (ACRS) | 0.2 | $326k | 40k | 8.15 | |
| Axogen (AXGN) | 0.1 | $223k | 250k | 0.89 |
